Hi Mozz, I came up a question the other day when I review the clinic trial design of PARA_002. Appreciate if you or anyone else know the answers.
In order to get FDA approved, do we need to meet all secondary endpoints of PARA_002? (there are 22 seconday endpoints, do we need to get statistically significant p<0.05 at all timepoints in the trial up to day168?)
Or we only need to meet the key secondary endpoints (specfically it is function at day53, pain and function at day 84, p value <0.05)?
https://clinicaltrials.gov/ct2/show/NCT04809376?term=pentosan&cntry=AU&draw=2&rank=2
Hi Mozz, I came up a question the other day when I review the...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 130186 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 11571 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |